Abstract 404P
Background
Cancers in AYA is being recognized as a disenfranchised niche field with its own unique epidemiology, cancer biology, risk factors, treatment implications & the massive socio-economic impact it bears on this most economically productive age-group. There is a paucity of well-collated published data from developing countries. Our study has tried to compile & analyze the pattern of AYA cancers from a large rural tertiary care teaching-hospital in South India & compare it to the published national data.
Methods
We compiled & analyzed the burden of AYA cancers in terms of demographic & site distribution, proportion, histopathologic diagnosis & other parameters over Jan.2019 to Dec.2022 from the medical records of large rural tertiary care teaching-hospital in South India. We compared our data on AYA cancers vis-à-vis the published national statistics.
Results
A total of 7973 patients were diagnosed with cancer between Jan.2019 to Dec.2022, 983(12.3%) occurred in AYA. 544(55.3%) were females. 104(10.6%), 126(12.9%), 153(15.5%), 226(23%) & 374(38.0%) occurred in the 15-19, 20-24, 25-29, 30-34 & 35-39 age groups respectively. The most common cancer overall was hematolymphoid malignancy(201, 20.4%), followed by thyroid(188, 19.12%). The most common hematolymphoid malignancy is acute leukaemia followed by non-Hodgkin lymphoma. The most common thyroid neoplasm was papillary thyroid carcinoma. Other common malignancies included Breast(113, 11.5%), Oral cavity(79, 8%), Central nervous system(65, 6.6%) & lower gastrointestinal tract(48, 4.9%).
Conclusions
AYA cancers deserve organizational support, multicenter collaboration, & resource-appropriate treatment adaptations with dedicated survivorship clinics. Mapping the epidemiology of AYA cancers will help improve surveillance, further focussed research & collaboration, guide resource allocation and national health policies, thus ultimately improve survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr. Vishwapriya Mahadev Godkhindi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06